Healthcare Burden Among Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Targeted Literature Review
Author(s)
Lesley-Ann Miller-Wilson, PhD, MBA1, Erin Mandal, BS2, Lincy Lal, PharmD, PhD1, Sarah Ronnebaum, PhD2, Laura Hope Atkinson, BS, MA2, Yuriy Edwards, MD, PhD1, Karissa Gable, MD3.
1Immunovant, Inc., New York, NY, USA, 2Thermo Fisher Scientific, Waltham, MA, USA, 3Duke University Hospital, Durham, NC, USA.
1Immunovant, Inc., New York, NY, USA, 2Thermo Fisher Scientific, Waltham, MA, USA, 3Duke University Hospital, Durham, NC, USA.
Presentation Documents
OBJECTIVES: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder typically characterized by progressive weakness and impaired sensory function. Novel treatments that target specific immune cells or signaling mechanisms involved in the pathogenesis of CIDP are being evaluated as alternative treatment options to immunoglobulins, corticosteroids, or other immunosuppressive agents. We assessed current evidence describing the burden of CIDP including clinical, humanistic, economic, and treatment-related aspects.
METHODS: A targeted literature review was conducted using a predefined search strategy and by manually searching for articles published any time in Embase and Medline as well as for conference abstracts published in 2021 or later. Records describing clinical, humanistic, economic, and treatment-related aspects of disease burden were included.
RESULTS: Among the 1749 records reviewed, 68 were relevant. Approximately 30%-50% of patients with CIDP were initially misdiagnosed and experienced a 4- to 30-month diagnostic delay after symptom onset. Patients with a >12-month treatment delay experienced a worsening disease course (ie, increased leg disability) compared with patients who started treatment earlier. CIDP was associated with significant clinical burden, including worse physical functioning than population norms (as measured by Short Form 36) and comorbidities (eg, diabetes, cardiovascular conditions, and depression). Notably, 60% of patients reported stopping or changing work due to CIDP-related symptoms, and higher unemployment rates were seen in patients compared with population norms. Patients with severe versus mild impairment also had increased medical costs and healthcare resource use. Physician and patient-reported reasons for lack of treatment satisfaction included efficacy declining over time, intravenous route of administration, and dosing frequency. Patients dissatisfied with their treatment were more likely to have worse disease status, disability, and quality of life.
CONCLUSIONS: The significant physical impact of and diagnostic delay in CIPD exacerbate treatment dissatisfaction, poor quality of life, loss of productivity, and increase costs and resource use among patients with CIDP.
METHODS: A targeted literature review was conducted using a predefined search strategy and by manually searching for articles published any time in Embase and Medline as well as for conference abstracts published in 2021 or later. Records describing clinical, humanistic, economic, and treatment-related aspects of disease burden were included.
RESULTS: Among the 1749 records reviewed, 68 were relevant. Approximately 30%-50% of patients with CIDP were initially misdiagnosed and experienced a 4- to 30-month diagnostic delay after symptom onset. Patients with a >12-month treatment delay experienced a worsening disease course (ie, increased leg disability) compared with patients who started treatment earlier. CIDP was associated with significant clinical burden, including worse physical functioning than population norms (as measured by Short Form 36) and comorbidities (eg, diabetes, cardiovascular conditions, and depression). Notably, 60% of patients reported stopping or changing work due to CIDP-related symptoms, and higher unemployment rates were seen in patients compared with population norms. Patients with severe versus mild impairment also had increased medical costs and healthcare resource use. Physician and patient-reported reasons for lack of treatment satisfaction included efficacy declining over time, intravenous route of administration, and dosing frequency. Patients dissatisfied with their treatment were more likely to have worse disease status, disability, and quality of life.
CONCLUSIONS: The significant physical impact of and diagnostic delay in CIPD exacerbate treatment dissatisfaction, poor quality of life, loss of productivity, and increase costs and resource use among patients with CIDP.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE498
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Neurological Disorders, No Additional Disease & Conditions/Specialized Treatment Areas